Baorui Liu

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo

Xianchuang Zheng, Xin Wang, Hui Mao et al. · Nature Communications · 2015 · 355 citations · Full text

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Shu Su, Bian Hu, Jie Shao et al. · Scientific Reports · 2016 · 299 citations · Full text

Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors

Fangjun Chen, Zhengyun Zou, Juan Du et al. · Journal of Clinical Investigation · 2019 · 217 citations · Full text

Successively activatable ultrasensitive probe for imaging tumour acidity and hypoxia

Xianchuang Zheng, Hui Mao, Da Huo et al. · Nature Biomedical Engineering · 2017 · 209 citations

Tumour Acidity, Engineering, Oncologic Imaging +9